Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy for Ovarian Carcinosarcoma

Gynecol Oncol; ePub 2016 May 2; Rauh-Hain, et al

Women with ovarian carcinosarcoma (OCS) are less likely to receive chemotherapy than women with high-grade papillary serous ovarian carcinoma (HG-PSOC) and OCS has worse prognosis across all FIGO stages. This according to a study of 45,153 women; 2,886 (6.39%) had OCS and 42,267 (93.61%) had HG-PSOC. Researchers found:

• African-American women had higher rate of OCS relative to white, Non-Hispanic women (7.84% vs 6.37%).

• Overall, women with OCS had a worse 5-year survival rate (26.63% vs 43.61%).

• The difference persisted for each FIGO disease stage I through IV, with 5-year survival consistently worse for women with OCS compared to those with HG-PSOC.

Citation: Rauh-Hain JA, Gonzalez R, Bregar AJ, et al. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. [Published online ahead of print May 2, 2016]. Gynecol Oncol. doi:doi.org/10.1016/j.ygyno.2016.04.025.